BioCryst Pharmaceuticals stock fell 1.85 percent on October 6

Published on 10/07/2026 at 07:18 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

BioCryst formed a seven-member Scientific Advisory Board on October 5, 2026, to guide external innovation. Q2 revenue reached USD 218.25 million, up 33.6 percent year over year.

BCRX, US09058V1035, Illustration mit AI erstellt.

BioCryst Pharmaceuticals stock (ISIN US09058V1035) closed at USD 7.95 on Nasdaq on October 6, 2026, down 1.85 percent from the prior close. On October 5, BioCryst announced a seven-member Scientific Advisory Board to support its shift toward external innovation.

External innovation gets a new board

According to GlobeNewswire on October 5, 2026, the board will advise BioCryst on pipeline expansion, external opportunities, translational science, clinical development and regulatory strategy.

The announcement gives the strategic shift a concrete operating structure. BioCryst is using outside scientific expertise to evaluate rare-disease programs while its commercial base remains centered on ORLADEYO, an oral therapy for hereditary angioedema.

Q2 profit changes the baseline

BioCryst reported second-quarter 2026 revenue of USD 218.25 million, up 33.6 percent year over year, according to StockTitan in its August 5, 2026 filing summary. GAAP operating profit was USD 98.5 million, while non-GAAP operating profit reached USD 113.2 million.

ORLADEYO contributed USD 158.2 million in Q2 2026, and USD 55.7 million of revenue came from the upfront payment tied to the European navenibart license. BioCryst raised full-year 2026 total revenue guidance to USD 690 million to USD 715 million, while maintaining ORLADEYO guidance of USD 625 million to USD 645 million, according to StockTitan.

Consensus points to USD 20.50

MarketBeat lists a Moderate Buy consensus from 12 analysts, with an average price target of USD 20.50, a high target of USD 32.00 and a low target of USD 9.00. The range shows how heavily the valuation depends on assumptions about pipeline execution rather than ORLADEYO sales alone.

The October 5 release also identifies the principal risk: external programs may take longer than expected, fail to produce positive results or fall short of commercial expectations. That makes the advisory board a strategic signal, while future clinical and business-development milestones remain the measurable tests.

BCRX stock closes at USD 7.95

BioCryst stock closed at USD 7.95 on Nasdaq on October 6, 2026, with a 52-week range of USD 6.00 to USD 11.22, market capitalization of USD 2.0 billion and volume of 3,940,350 shares.